Karyopharm Therapeutics (KPTI) Operating Expenses (2012 - 2025)

Karyopharm Therapeutics has reported Operating Expenses for 14 years, with the latest figure at $51.9 million in Q4 2025.

• For the quarter ending Q4 2025, Operating Expenses fell 16.01% year-over-year to $51.9 million; the trailing twelve-month figure through Dec 2025 stood at $236.8 million (down 10.54% YoY), and the FY2025 full-year result was $236.8 million, down 10.54% from the prior year.
• Operating Expenses for Q4 2025 stood at $51.9 million, down from $59.3 million in the prior quarter.
• The five-year high for Operating Expenses was $82.6 million in Q2 2022, with the low at $933000.0 in Q1 2021.
• Historically, Operating Expenses has averaged $65.5 million across 5 years, with a median of $67.2 million in 2023.
• The largest YoY upside for Operating Expenses was 17993.18% in 2021 against a maximum downside of 98.58% in 2021.
• Karyopharm Therapeutics' Operating Expenses stood at $79.3 million in 2021, then retreated by 14.95% to $67.4 million in 2022, then grew by 6.09% to $71.6 million in 2023, then declined by 13.6% to $61.8 million in 2024, then dropped by 16.01% to $51.9 million in 2025.
• The last three Operating Expenses figures came in at $51.9 million (Q4 2025), $59.3 million (Q3 2025), and $62.3 million (Q2 2025), per Business Quant data.